Cytosorbents Crp
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. The company's flagship product is CytoSorb, an extracorporeal blood purification cartridge for the treatment of massive inflamm… Read more
Cytosorbents Crp (CTSO) - Total Liabilities
Latest total liabilities as of September 2025: $36.73 Million USD
Based on the latest financial reports, Cytosorbents Crp (CTSO) has total liabilities worth $36.73 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Cytosorbents Crp - Total Liabilities Trend (2004–2024)
This chart illustrates how Cytosorbents Crp's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Cytosorbents Crp Competitors by Total Liabilities
The table below lists competitors of Cytosorbents Crp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Outset Medical Inc
NASDAQ:OM
|
USA | $137.54 Million |
|
SEOHAN Const. & Eng.co.Ltd
KQ:011370
|
Korea | ₩666.51 Billion |
|
NVH Korea Inc
KQ:067570
|
Korea | ₩1.15 Trillion |
|
Hwa Fong Rubber (Thailand) Public Company Limited
BK:HFT
|
Thailand | ฿385.79 Million |
|
Rockwell Medical Inc
NASDAQ:RMTI
|
USA | $20.47 Million |
|
Ubiqconn Technology, Inc.
TW:6928
|
Taiwan | NT$663.61 Million |
|
Kayseri Seker Fabrikasi AS
IS:KAYSE
|
Turkey | TL13.18 Billion |
|
Turmalina Metals Corp
OTCQB:TBXXF
|
USA | $670.68K |
Liability Composition Analysis (2004–2024)
This chart breaks down Cytosorbents Crp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 4.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.80 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cytosorbents Crp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cytosorbents Crp (2004–2024)
The table below shows the annual total liabilities of Cytosorbents Crp from 2004 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $36.26 Million | +20.94% |
| 2023-12-31 | $29.99 Million | +7.64% |
| 2022-12-31 | $27.86 Million | +3.40% |
| 2021-12-31 | $26.94 Million | +150.97% |
| 2020-12-31 | $10.73 Million | -55.21% |
| 2019-12-31 | $23.96 Million | +51.56% |
| 2018-12-31 | $15.81 Million | +14.25% |
| 2017-12-31 | $13.84 Million | +36.12% |
| 2016-12-31 | $10.17 Million | +234.06% |
| 2015-12-31 | $3.04 Million | -32.45% |
| 2014-12-31 | $4.51 Million | -75.39% |
| 2013-12-31 | $18.31 Million | +22.36% |
| 2012-12-31 | $14.96 Million | +729.43% |
| 2011-12-31 | $1.80 Million | -21.44% |
| 2010-12-31 | $2.30 Million | +136.57% |
| 2009-12-31 | $970.76K | -5.54% |
| 2008-12-31 | $1.03 Million | +13.32% |
| 2007-12-31 | $906.87K | -16.19% |
| 2006-12-31 | $1.08 Million | +961.13% |
| 2005-12-31 | $101.97K | +13.30% |
| 2004-12-31 | $90.00K | -- |